Hamaz Pharmaceuticals (Pvt) Ltd.
Private pharmaceutical manufacturer · Multan · Pakistan
Multan-based pharmaceutical manufacturer appearing in DRAP product records as a contract manufacturing site.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Hamaz Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 13-KM Bosan Road, Lutfabad, Multan, Pakistan
- Website
- hamazpharma.com ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 63%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Foxime | Cefotaxime | 250 mg | Injection | 25's | 052915 | PKR 2,505.17 | PKR 100.21/vial/unit | Near median |
| Foxime | Cefotaxime | 250 mg | Injection | 1's | 052915 | PKR 110.89 | PKR 110.89/vial/unit | 5% above median |
| Geclomaz | Valganciclovir | 450 mg | Tablet | 60's | 107260 | PKR 130,361.68 | PKR 2,172.69/tablet | Near median |
| Graflimus | Tacrolimus | 0.5 mg | Capsule | 50's | 111800 | PKR 6,139.17 | PKR 122.78/capsule | 115% above median |
| Hamadar | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 10's | 021334 | PKR 262.27 | PKR 26.23/tablet | 216% above median |
| Hamadar | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 20's | 021334 | PKR 524.54 | PKR 26.23/tablet | 216% above median |
| Hamadar | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg/5 mL | Suspension | 15ml | 027685 | PKR 46.48 | PKR 3.10/mL | 41% above median |
| Hamazol | Omeprazole | 20 mg | Capsule | 14's | 026094 | PKR 219.42 | PKR 15.67/capsule | 20% below median |
| Hamazol | Omeprazole | 20 mg | Capsule | 10x10s | 026094 | PKR 1,416.32 | PKR 14.16/capsule | 28% below median |
| Hamazox | Azithromycin | 250 mg | Tablet | 6's | 106023 | PKR 230.18 | PKR 38.36/tablet | 19% below median |
| Hamazox | Azithromycin | 200 mg/5 mL | Oral suspension | 15ml | 106024 | PKR 247.62 | PKR 16.51/mL | 18% below median |
| Hamazox | Azithromycin | 100 mg/5 mL | Oral suspension | 30ml | 106025 | PKR 150.07 | PKR 5.00/mL | 11% below median |
| Hamazox | Azithromycin | 500 mg | Tablet | 6's | 108354 | PKR 383.63 | PKR 63.94/tablet | 25% below median |
| Hamozain | Anastrozole | 1 mg | Tablet | 30's | 107258 | PKR 8,470.35 | PKR 282.35/tablet | 17% below median |
| Hamzolid | Linezolid | 200 mg | Injection | 100ml | 102627 | PKR 428.76 | PKR 4.29/mL | 39% below median |
| Hemso Dry Powder InjectionRegistry verified | Esomeprazole as sodium | — | — | — | 108349Official source ↗ | No indexed price | — | — |
| Iburin Forte | Ibuprofen | 200 mg/5 mL | Suspension | 60ml | 114147 | PKR 52.81 | PKR 0.88/mL | 31% below median |
| Klaratil | Loratadine | 10 mg | Tablet | 10's | 114148 | PKR 100.06 | PKR 10.01/tablet | 30% below median |
| Klaratil | Loratadine | 5 mg/5 mL | Syrup | 60ml | 114149 | PKR 68.10 | PKR 1.14/mL | 33% below median |
| Laphenor | Hydrocortisone | 1% w/w | Ointment | 20gm | 080097 | PKR 43.41 | PKR 2.17/g | No comparator |
| Larex | Albendazole | 200 mg | Tablet | 2's | 046956 | PKR 33.91 | PKR 16.96/tablet | 9% above median |
| Larex | Albendazole | 200 mg | Tablet | 10's | 046956 | PKR 153.24 | PKR 15.32/tablet | Near median |
| Lavizole | Clotrimazole | 10 g | Cream | 10gm | 080101 | PKR 63.84 | PKR 6.38/g | No comparator |
| lburin | Ibuprofen | 200 mg | Tablet | 50x10s | 005124 | PKR 1,333.25 | PKR 2.67/tablet | 18% above median |
| lburin | Ibuprofen | 400 mg | Tablet | 250's | 005894 | PKR 919.73 | PKR 3.68/tablet | Near median |
| lburin | Ibuprofen | 100 mg/5 mL | Suspension | 90ml | 027686 | PKR 101.62 | PKR 1.13/mL | 19% above median |
| lburin | Ibuprofen | 600 mg | Tablet | 3x10s | 064634 | PKR 179.52 | PKR 5.98/tablet | 7% below median |
| Lonosal | Sodium chloride + Sodium citrate + Potassium chloride + Glucose | 3 mg + 2.9 mg + 1.5 mg + 20 mg | Sachet | 20's | 080671 | PKR 398.94 | PKR 19.95/sachet | No comparator |
| Lowvas | Losartan | 50 mg | Tablet | 2x10s | 024525 | PKR 1,441.88 | PKR 72.09/tablet | 247% above median |
| LR-250 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 103366 | PKR 12,331.98 | PKR 102.77/tablet | 7% above median |
| Lupin | Levofloxacin | 250 mg | Tablet | 5x10's | 064635 | PKR 2,253.26 | PKR 45.07/tablet | 7% below median |
| Lupin | Levofloxacin | 250 mg | Tablet | 10's | 064635 | PKR 498.67 | PKR 49.87/tablet | Near median |
| Lupin | Levofloxacin | 500 mg | Tablet | 5x10's | 064636 | PKR 3,749.45 | PKR 74.99/tablet | 5% below median |
| Lupin | Levofloxacin | 500 mg | Tablet | 10's | 064636 | PKR 829.79 | PKR 82.98/tablet | Near median |
| Lupin | Levofloxacin | 500 mg | IV infusion | 100ml x 50s | 084182 | PKR 22,532.65 | PKR 4.51/mL | 21% below median |
| Lupin | Levofloxacin | 500 mg | IV infusion | 100ml x 1s | 084182 | PKR 498.67 | PKR 4.99/mL | 12% below median |
| Micohyd | Miconazole + Hydrocortisone | 2% + 1% | Cream | 10gm | 113259 | PKR 68.65 | PKR 6.87/g | 35% below median |
| Micostatin | Nystatin | 100000 IU/mL | Oral drops | 30ml | 046962 | PKR 95.74 | PKR 3.19/mL | 47% above median |
| Micostatin | Nystatin | 100000 IU | Tablet | 10s | 046966 | PKR 35.90 | PKR 3.59/tablet | No comparator |
| Monistat | Miconazole | 2 % | Cream | 10gm | 116619 | PKR 69.49 | PKR 6.95/g | 8% below median |
| Nixin | Ciprofloxacin | 500 mg | Tablet | 5x10's | 064640 | PKR 1,937.82 | PKR 38.76/tablet | 10% below median |
| Nixin | Ciprofloxacin | 500 mg | Tablet | 10's | 064640 | PKR 428.86 | PKR 42.89/tablet | Near median |
| Nixin | Ciprofloxacin | 250 mg | Tablet | 10's | 064641 | PKR 259.31 | PKR 25.93/tablet | Near median |
| Nixin | Ciprofloxacin | 125 mg/5 mL | Suspension | 60ml | 076988 | PKR 222.36 | PKR 3.71/mL | Near median |
| Nixin | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 076989 | PKR 319.15 | PKR 5.32/mL | Near median |
| Nixin | Ciprofloxacin | 200 mg | IV infusion | 100ml x 50s | 084181 | PKR 9,013.06 | PKR 1.80/mL | 21% below median |
| Nixin | Ciprofloxacin | 200 mg | IV infusion | 100ml x 1s | 084181 | PKR 199.47 | PKR 1.99/mL | 12% below median |
| Osengo | Oseltamivir | 75 mg | Capsule | 10's | 104521 | PKR 1,248.58 | PKR 124.86/capsule | Near median |
| Panamaz | Mefenamic acid | 50 mg/5 mL | Suspension | 60ml | 038265 | PKR 71.77 | PKR 1.20/mL | No comparator |
| Phosoquine | Chloroquine | 250 mg | Tablet | 20x10s | 005530 | PKR 672.63 | PKR 3.36/tablet | 118% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.
